Quantum Genomics : initiation of a First-in-Human clinical study with QGC001, its lead compound for the treatment of hypertension

April 13th 2012 - Quantum Genomics (NYSE Euronext Paris : MLQGC), following the approval from the French Agency for Safety of Health Products (AFSSAPS), announces the initiation of a phase I clinical study in healthy volunteers with its product QGC001. QGC001 is the first of a new class of drugs that is able to monitor high blood pressure by inhibiting the aminopeptidase A enzyme (APA) at the brain level.

Arterial hypertension affects an estimated 1 billion people worldwide (13 million people in France). Despite the availability of many antihypertensive drugs, 30% to 60% of patients diagnosed with hypertension do not have their blood pressure properly controlled by current medications for various reasons (49% in France ([1])). Moreover, the overall incidence of resistant hypertension to at least three antihypertensive drugs (including a diuretic) is estimatedaround 8% to 12% of the hypertensive population... Quantum Genomics' Press Release -